Publicaciones en colaboración con investigadores/as de Hospital de Cruces (74)

2024

  1. De-imFAR phase II project: a study protocol for a cluster randomised implementation trial to evaluate the effectiveness of de-implementation strategies to reduce low-value statin prescribing in the primary prevention of cardiovascular disease

    BMJ Open, Vol. 14, Núm. 4

  2. Increased incidence of pediatric type 1 diabetes during the pandemic in Biscay, Spain

    Endocrinologia, Diabetes y Nutricion, Vol. 71, Núm. 8, pp. 332-339

  3. Novel risk loci for COVID-19 hospitalization among admixed American populations

    eLife, Vol. 13

2023

  1. A Red Herring to Iatrogenic Pneumothorax

    Archivos de Bronconeumologia, Vol. 59, Núm. 6, pp. 387-388

  2. A second update on mapping the human genetic architecture of COVID-19

    Nature

  3. Altered Red Blood Cell Fatty Acid and Serum Adipokine Profiles in Subjects with Obesity

    Biomedicines, Vol. 11, Núm. 12

  4. Gender differences in the management of acute psychiatric episodes in the emergency department: a cross-sectional analysis of the 2017–2019 triennium

    Archives of Women's Mental Health, Vol. 26, Núm. 6, pp. 777-783

  5. New antioxidant therapy for hard-to-heal neuroischaemic diabetic foot ulcers with deep exposure

    Journal of Wound Care, Vol. 32, Núm. 4, pp. 238-246

  6. Nurse-Supervised Exercise for People with Stage IV Cancer: The EFICANCER Randomized Clinical Trial

    Seminars in Oncology Nursing, Vol. 39, Núm. 4

  7. Violence in first-episode psychosis: Evidence from an early intervention in psychosis programme

    BJPsych Open, Vol. 9, Núm. 5

2022

  1. Effectiveness of the vagino-rectal exudate self-sampling for prenatal screening of Streptococcus agalactiae infection. GALL study

    Atencion Primaria, Vol. 54, Núm. 6

  2. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial

    The Lancet Infectious Diseases, Vol. 22, Núm. 3, pp. 329-340

  3. Modelling the risk of hospital admission of lab confirmed SARS-CoV-2-infected patients in primary care: a population-based study

    Internal and emergency medicine, Vol. 17, Núm. 4, pp. 1211-1221

  4. Novel genes and sex differences in COVID-19 severity

    Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806

2021

  1. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

    The Lancet, Vol. 398, Núm. 10295, pp. 121-130

2020

  1. A new clinical score to identify children at low risk for appendicitis

    American Journal of Emergency Medicine, Vol. 38, Núm. 3, pp. 554-561

  2. The urinary transcriptome as a source of biomarkers for prostate cancer

    Cancers, Vol. 12, Núm. 2

  3. Wound dressing selection is critical to enhance platelet-rich fibrin activities in wound care

    International Journal of Molecular Sciences, Vol. 21, Núm. 2

2019

  1. Changing epidemiology of nontuberculous mycobacterial lung disease over the last two decades in a region of the Basque Country

    ERJ Open Research, Vol. 5, Núm. 4

  2. Ensuring secure health data exchange across Europe. SHIELD project

    HEALTHINF 2019 - 12th International Conference on Health Informatics, Proceedings; Part of 12th International Joint Conference on Biomedical Engineering Systems and Technologies, BIOSTEC 2019